Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
|Videos|November 10, 2022
Dr. Hafron explains the benefits of Jelmyto in UTUC since its approval
Author(s)Urology Times staff
"We're seeing that it's beneficial to the patient—it’s easier, they don't require a general anesthetic, and we don't have to bring him to the hospital," says Dr. Hafron.
Advertisement
During the
Advertisement
Related to this article
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Urocross Expander System enters US commercial use for symptomatic BPH
3
Three-year data show durable responses with mitomycin intravesical solution
4
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution
5